{
  "doc_id": "3",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "成人2型糖尿病胰岛素临床应用的中国专家共识",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "成人2型糖尿病胰岛素临床应用的中国专家共识",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T1",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T2",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R0",
              "head_entity_id": "T1",
              "tail_entity_id": "T0"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R1",
              "head_entity_id": "T2",
              "tail_entity_id": "T0"
            }
          ],
          "sentence_en": "Chinese expert consensus on the clinical application of insulin in adults with type 2 diabetes"
        }
      ],
      "paragraph_en": "Chinese expert consensus on the clinical application of insulin in adults with type 2 diabetes"
    },
    {
      "paragraph_id": "1",
      "paragraph": "糖尿病已成为严重威胁国人健康的最重要的慢性非传染性疾病之一，但糖尿病控制状况在我国并不容乐观，甚至按纵向比较，血糖控制情况亦无显著改善。2011年公布现状调查显示口服药联合胰岛素治疗的患者中85%HbA1c控制未达标(≥7.o%)糖尿病相关治疗费用中约80%用于糖尿病并发症的治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病已成为严重威胁国人健康的最重要的慢性非传染性疾病之一，但糖尿病控制状况在我国并不容乐观，甚至按纵向比较，血糖控制情况亦无显著改善。2011年公布现状调查显示口服药联合胰岛素治疗的患者中85%HbA1c控制未达标(≥7.o%)糖尿病相关治疗费用中约80%用于糖尿病并发症的治疗。",
          "start_idx": 0,
          "end_idx": 141,
          "entities": [
            {
              "entity_id": "T3",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T4",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 34,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T5",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 55,
              "end_idx": 57,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T6",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 81,
              "end_idx": 83,
              "entity_en": "oral"
            },
            {
              "entity_id": "T7",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 89,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T8",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 98,
              "end_idx": 103,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T9",
              "entity": "控制未达标(≥7.o%)",
              "entity_type": "Test_Value",
              "start_idx": 103,
              "end_idx": 115,
              "entity_en": "Control not up to standard (≥7.o%)"
            },
            {
              "entity_id": "T10",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 115,
              "end_idx": 118,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T11",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 131,
              "end_idx": 134,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R2",
              "head_entity_id": "T5",
              "tail_entity_id": "T4"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R3",
              "head_entity_id": "T7",
              "tail_entity_id": "T10"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R4",
              "head_entity_id": "T8",
              "tail_entity_id": "T10"
            }
          ],
          "sentence_en": "Diabetes has become one of the most important chronic non-communicable diseases that seriously threatens the health of Chinese people, but the control of diabetes in my country is not optimistic. Even in longitudinal comparison, there is no significant improvement in blood sugar control. A survey published in 2011 showed that 85% of patients treated with oral medication combined with insulin had HbA1c control that failed to reach the target (≥7.0%). About 80% of the treatment costs related to diabetes were used for the treatment of diabetic complications."
        }
      ],
      "paragraph_en": "Diabetes has become one of the most important chronic non-communicable diseases that seriously threatens the health of Chinese people, but the control of diabetes in my country is not optimistic. Even in longitudinal comparison, there is no significant improvement in blood sugar control. A survey published in 2011 showed that 85% of patients treated with oral medication combined with insulin had HbA1c control that failed to reach the target (≥7.0%). About 80% of the treatment costs related to diabetes were used for the treatment of diabetic complications."
    },
    {
      "paragraph_id": "2",
      "paragraph": "众所周知，2型糖尿病患者胰岛β细胞功能随病程进展逐渐恶化。由此推论，随病程进展，为取得血糖最佳控制，大部分2型糖尿病患者似乎最终均需胰岛素治疗。然而，由于社会、经济和心理因素，胰岛素使用不足和使用过度的情况在我国同时并存。因此，规范胰岛素治疗对于改善糖尿病管理、提高广大医护人员的临床实践水平具有重要意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "众所周知，2型糖尿病患者胰岛β细胞功能随病程进展逐渐恶化。由此推论，随病程进展，为取得血糖最佳控制，大部分2型糖尿病患者似乎最终均需胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 72,
          "entities": [
            {
              "entity_id": "T12",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T13",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T14",
              "entity": "胰岛β细胞功能随病程进展逐渐恶化",
              "entity_type": "Pathogenesis",
              "start_idx": 12,
              "end_idx": 28,
              "entity_en": "Pancreatic β-cell function gradually deteriorates as the disease progresses"
            },
            {
              "entity_id": "T15",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 43,
              "end_idx": 45,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T16",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 58,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T17",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 53,
              "end_idx": 55,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T18",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 69,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R5",
              "head_entity_id": "T13",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R6",
              "head_entity_id": "T14",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R7",
              "head_entity_id": "T15",
              "tail_entity_id": "T16"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R8",
              "head_entity_id": "T17",
              "tail_entity_id": "T16"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R9",
              "head_entity_id": "T18",
              "tail_entity_id": "T16"
            }
          ],
          "sentence_en": "It is well known that pancreatic β-cell function in patients with type 2 diabetes gradually deteriorates as the disease progresses. Therefore, it is inferred that most patients with type 2 diabetes will eventually require insulin treatment to achieve optimal blood sugar control as the disease progresses."
        },
        {
          "sentence_id": "1",
          "sentence": "然而，由于社会、经济和心理因素，胰岛素使用不足和使用过度的情况在我国同时并存。",
          "start_idx": 72,
          "end_idx": 111,
          "entities": [
            {
              "entity_id": "T19",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "However, due to social, economic and psychological factors, under- and over-use of insulin coexist in our country."
        },
        {
          "sentence_id": "2",
          "sentence": "因此，规范胰岛素治疗对于改善糖尿病管理、提高广大医护人员的临床实践水平具有重要意义。",
          "start_idx": 111,
          "end_idx": 153,
          "entities": [
            {
              "entity_id": "T20",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T21",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R10",
              "head_entity_id": "T20",
              "tail_entity_id": "T21"
            }
          ],
          "sentence_en": "Therefore, standardized insulin therapy is of great significance for improving diabetes management and enhancing the clinical practice level of medical staff."
        }
      ],
      "paragraph_en": "It is well known that pancreatic β-cell function in patients with type 2 diabetes gradually deteriorates as the disease progresses. It is inferred that, as the disease progresses, most patients with type 2 diabetes seem to eventually require insulin treatment in order to achieve optimal blood sugar control. However, due to social, economic, and psychological factors, insufficient and excessive use of insulin coexist in my country. Therefore, standardized insulin treatment is of great significance for improving diabetes management and improving the clinical practice level of medical staff."
    },
    {
      "paragraph_id": "3",
      "paragraph": "目前临床应用的胰岛素包括动物胰岛素、人胰岛素及胰岛素类似物。其中，人胰岛素具有免疫原性低、长期使用安全可靠、效价比高等优点，在临床中应用最为广泛，在2型糖尿病血糖管理中作用突出。胰岛素类似物通过改变人胰岛素结构从而改变其药代动力学特性，可分为超短效胰岛素类似物和长效胰岛素类似物。因起效和持续时间不同，胰岛素类似物有其各自的特点，但其使用和剂量调整原则与人胰岛素基本相同（表1）。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前临床应用的胰岛素包括动物胰岛素、人胰岛素及胰岛素类似物。其中，人胰岛素具有免疫原性低、长期使用安全可靠、效价比高等优点，在临床中应用最为广泛，在2型糖尿病血糖管理中作用突出。",
          "start_idx": 0,
          "end_idx": 89,
          "entities": [
            {
              "entity_id": "T22",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T23",
              "entity": "动物胰岛素",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Animal insulin"
            },
            {
              "entity_id": "T24",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Human insulin"
            },
            {
              "entity_id": "T25",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 29,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T26",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 37,
              "entity_en": "Human insulin"
            },
            {
              "entity_id": "T27",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 79,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T28",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 74,
              "end_idx": 76,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T29",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 79,
              "end_idx": 81,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R11",
              "head_entity_id": "T28",
              "tail_entity_id": "T27"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R12",
              "head_entity_id": "T29",
              "tail_entity_id": "T27"
            }
          ],
          "sentence_en": "The insulin currently used in clinical practice includes animal insulin, human insulin and insulin analogs. Among them, human insulin has the advantages of low immunogenicity, long-term safety and reliability, and high cost-effectiveness. It is the most widely used in clinical practice and plays an outstanding role in blood sugar management in type 2 diabetes."
        },
        {
          "sentence_id": "1",
          "sentence": "胰岛素类似物通过改变人胰岛素结构从而改变其药代动力学特性，可分为超短效胰岛素类似物和长效胰岛素类似物。",
          "start_idx": 89,
          "end_idx": 140,
          "entities": [
            {
              "entity_id": "T30",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T31",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "Human insulin"
            },
            {
              "entity_id": "T32",
              "entity": "超短效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 41,
              "entity_en": "Ultra-short-acting insulin analogs"
            },
            {
              "entity_id": "T33",
              "entity": "长效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 50,
              "entity_en": "Long-acting insulin analogs"
            }
          ],
          "relations": [],
          "sentence_en": "Insulin analogs change the pharmacokinetic properties of human insulin by changing its structure, and can be divided into ultra-short-acting insulin analogs and long-acting insulin analogs."
        },
        {
          "sentence_id": "2",
          "sentence": "因起效和持续时间不同，胰岛素类似物有其各自的特点，但其使用和剂量调整原则与人胰岛素基本相同（表1）。",
          "start_idx": 140,
          "end_idx": 190,
          "entities": [
            {
              "entity_id": "T34",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 17,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T35",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41,
              "entity_en": "Human insulin"
            }
          ],
          "relations": [],
          "sentence_en": "Insulin analogs have their own characteristics due to different onset and duration of action, but their use and dosage adjustment principles are basically the same as those of human insulin (Table 1)."
        }
      ],
      "paragraph_en": "At present, the insulin used in clinical practice includes animal insulin, human insulin and insulin analogs. Among them, human insulin has the advantages of low immunogenicity, long-term safety and reliability, and high cost-effectiveness. It is the most widely used in clinical practice and plays an outstanding role in blood sugar management in type 2 diabetes. Insulin analogs can be divided into ultra-short-acting insulin analogs and long-acting insulin analogs by changing the structure of human insulin and thus its pharmacokinetic properties. Due to different onset and duration, insulin analogs have their own characteristics, but their use and dosage adjustment principles are basically the same as those of human insulin (Table 1)."
    },
    {
      "paragraph_id": "4",
      "paragraph": "一、合理选择胰岛素治疗时机",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、合理选择胰岛素治疗时机",
          "start_idx": 0,
          "end_idx": 13,
          "entities": [
            {
              "entity_id": "T36",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "1. Rationally choose the timing of insulin treatment"
        }
      ],
      "paragraph_en": "1. Rationally choose the timing of insulin treatment"
    },
    {
      "paragraph_id": "5",
      "paragraph": "对于2型糖尿病患者而言，尽早启动胰岛素治疗能减轻胰岛β细胞的负荷，尽快纠正高血糖状态，迅速解除高糖毒性，改善胰岛素抵抗，保护甚至逆转残存β细胞功能。对于胰岛素起始治疗的时机，不同学术组织的推荐有所不同(表2)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于2型糖尿病患者而言，尽早启动胰岛素治疗能减轻胰岛β细胞的负荷，尽快纠正高血糖状态，迅速解除高糖毒性，改善胰岛素抵抗，保护甚至逆转残存β细胞功能。",
          "start_idx": 0,
          "end_idx": 74,
          "entities": [
            {
              "entity_id": "T37",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T38",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T39",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T40",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T41",
              "entity": "高糖毒性",
              "entity_type": "Pathogenesis",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "High sugar toxicity"
            },
            {
              "entity_id": "T42",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 54,
              "end_idx": 59,
              "entity_en": "Insulin resistance"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R13",
              "head_entity_id": "T38",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R14",
              "head_entity_id": "T39",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R15",
              "head_entity_id": "T41",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R16",
              "head_entity_id": "T42",
              "tail_entity_id": "T37"
            }
          ],
          "sentence_en": "For patients with type 2 diabetes, starting insulin therapy as early as possible can reduce the burden on pancreatic β cells, correct hyperglycemia as soon as possible, quickly relieve high glucose toxicity, improve insulin resistance, and protect or even reverse the function of remaining β cells."
        },
        {
          "sentence_id": "1",
          "sentence": "对于胰岛素起始治疗的时机，不同学术组织的推荐有所不同(表2)。",
          "start_idx": 74,
          "end_idx": 105,
          "entities": [
            {
              "entity_id": "T43",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "Different academic organizations have different recommendations on the timing of initiating insulin therapy (Table 2)."
        }
      ],
      "paragraph_en": "For patients with type 2 diabetes, starting insulin therapy as early as possible can reduce the load on pancreatic β cells, correct hyperglycemia as soon as possible, quickly relieve hyperglycemia toxicity, improve insulin resistance, and protect or even reverse the function of remaining β cells. Different academic organizations have different recommendations on the timing of starting insulin therapy (Table 2)."
    },
    {
      "paragraph_id": "6",
      "paragraph": "多项研究表明，亚裔不仅胰岛β细胞胰岛素分泌储备能力较西方白种人低，糖脂毒性及氧化应激等对β细胞毒害作用亦更为显著。因此，中国2型糖尿病患者应适时启动胰岛素治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "多项研究表明，亚裔不仅胰岛β细胞胰岛素分泌储备能力较西方白种人低，糖脂毒性及氧化应激等对β细胞毒害作用亦更为显著。因此，中国2型糖尿病患者应适时启动胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 80,
          "entities": [
            {
              "entity_id": "T44",
              "entity": "亚裔不仅胰岛β细胞胰岛素分泌储备能力较西方白种人低",
              "entity_type": "Pathogenesis",
              "start_idx": 7,
              "end_idx": 32,
              "entity_en": "Asians not only have lower insulin secretion reserve capacity of pancreatic β cells than Western Caucasians"
            },
            {
              "entity_id": "T45",
              "entity": "糖脂毒性及氧化应激等对β细胞毒害作用亦更为显著",
              "entity_type": "Pathogenesis",
              "start_idx": 33,
              "end_idx": 56,
              "entity_en": "Glucose and lipid toxicity and oxidative stress also have more significant toxic effects on β cells"
            },
            {
              "entity_id": "T46",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 67,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T47",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 62,
              "end_idx": 64,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T48",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 77,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R17",
              "head_entity_id": "T47",
              "tail_entity_id": "T46"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R18",
              "head_entity_id": "T48",
              "tail_entity_id": "T46"
            }
          ],
          "sentence_en": "Many studies have shown that Asians not only have lower insulin secretion reserve capacity in pancreatic β cells than Western whites, but also have more significant toxic effects on β cells due to glucolipid toxicity and oxidative stress. Therefore, Chinese patients with type 2 diabetes should start insulin treatment at the right time."
        }
      ],
      "paragraph_en": "Many studies have shown that Asians not only have lower insulin secretion reserve capacity in pancreatic β cells than Western whites, but also have more significant toxic effects on β cells due to glucolipid toxicity and oxidative stress. Therefore, Chinese patients with type 2 diabetes should start insulin treatment at the right time."
    },
    {
      "paragraph_id": "7",
      "paragraph": "本共识建议，对于2型糖尿病患者，以下情况应给予胰岛素治疗：(1)急性并发症或严重慢性并发症；(2)应激情况(感染、外伤、手术等)；(3)严重合并症，肝肾功能不全；(4)妊娠期间。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "本共识建议，对于2型糖尿病患者，以下情况应给予胰岛素治疗：(1)急性并发症或严重慢性并发症；(2)应激情况(感染、外伤、手术等)；(3)严重合并症，肝肾功能不全；(4)妊娠期间。",
          "start_idx": 0,
          "end_idx": 89,
          "entities": [
            {
              "entity_id": "T49",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T50",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T51",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T52",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 80,
              "entity_en": "Liver and kidney dysfunction"
            },
            {
              "entity_id": "T53",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 74,
              "end_idx": 75,
              "entity_en": "liver"
            },
            {
              "entity_id": "T54",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 75,
              "end_idx": 76,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R19",
              "head_entity_id": "T50",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R20",
              "head_entity_id": "T51",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R21",
              "head_entity_id": "T53",
              "tail_entity_id": "T52"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R22",
              "head_entity_id": "T54",
              "tail_entity_id": "T52"
            }
          ],
          "sentence_en": "This consensus recommends that patients with type 2 diabetes should be given insulin therapy in the following situations: (1) acute complications or severe chronic complications; (2) stressful situations (infection, trauma, surgery, etc.); (3) severe complications, liver and kidney dysfunction; and (4) during pregnancy."
        }
      ],
      "paragraph_en": "This consensus recommends that patients with type 2 diabetes should be given insulin therapy in the following situations: (1) acute complications or severe chronic complications; (2) stressful situations (infection, trauma, surgery, etc.); (3) severe complications, liver and kidney dysfunction; and (4) during pregnancy."
    },
    {
      "paragraph_id": "8",
      "paragraph": "以下情况可给予胰岛素单药治疗，亦可给予口服药和胰岛素联合应用：(1)新诊断2型糖尿病患者，HbA1c≥9.0%且糖尿病症状明显；(2)在采用有效的生活方式干预及2种或2种以上口服降糖药物次大剂量治疗3个月后血糖仍不达标(HbA1c≥7.0%)的患者；(3)病程中出现无明显诱因的体重下降者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "以下情况可给予胰岛素单药治疗，亦可给予口服药和胰岛素联合应用：(1)新诊断2型糖尿病患者，HbA1c≥9.0%且糖尿病症状明显；(2)在采用有效的生活方式干预及2种或2种以上口服降糖药物次大剂量治疗3个月后血糖仍不达标(HbA1c≥7.0%)的患者；(3)病程中出现无明显诱因的体重下降者。",
          "start_idx": 0,
          "end_idx": 145,
          "entities": [
            {
              "entity_id": "T55",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T56",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "oral"
            },
            {
              "entity_id": "T57",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T58",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 42,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T59",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 37,
              "end_idx": 39,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T60",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 45,
              "end_idx": 50,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T61",
              "entity": "≥9.0%",
              "entity_type": "Test_Value",
              "start_idx": 50,
              "end_idx": 55,
              "entity_en": "≥9.0%"
            },
            {
              "entity_id": "T62",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 59,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T63",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 73,
              "end_idx": 79,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T64",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 87,
              "end_idx": 89,
              "entity_en": "oral"
            },
            {
              "entity_id": "T65",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 103,
              "end_idx": 105,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T66",
              "entity": "不达标",
              "entity_type": "Test_Value",
              "start_idx": 106,
              "end_idx": 109,
              "entity_en": "Not up to standard"
            },
            {
              "entity_id": "T67",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 110,
              "end_idx": 115,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T68",
              "entity": "≥7.0%",
              "entity_type": "Test_Value",
              "start_idx": 115,
              "end_idx": 120,
              "entity_en": "≥7.0%"
            },
            {
              "entity_id": "T69",
              "entity": "体重下降",
              "entity_type": "Symptom",
              "start_idx": 139,
              "end_idx": 143,
              "entity_en": "Weight loss"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R23",
              "head_entity_id": "T59",
              "tail_entity_id": "T58"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R24",
              "head_entity_id": "T60",
              "tail_entity_id": "T58"
            }
          ],
          "sentence_en": "Insulin monotherapy or oral medication and insulin combination therapy can be used in the following situations: (1) patients with newly diagnosed type 2 diabetes, HbA1c ≥ 9.0% and obvious symptoms of diabetes; (2) patients whose blood sugar level remains below target (HbA1c ≥ 7.0%) after 3 months of effective lifestyle intervention and submaximal dose treatment with 2 or more oral glucose-lowering drugs; (3) patients who experience weight loss without obvious cause during the course of the disease."
        }
      ],
      "paragraph_en": "Insulin monotherapy or oral medication and insulin combination therapy can be used in the following situations: (1) patients with newly diagnosed type 2 diabetes, HbA1c ≥ 9.0% and obvious symptoms of diabetes; (2) patients whose blood sugar level remains below target (HbA1c ≥ 7.0%) after 3 months of effective lifestyle intervention and submaximal dose treatment with 2 or more oral glucose-lowering drugs; (3) patients who experience weight loss without obvious cause during the course of the disease."
    },
    {
      "paragraph_id": "9",
      "paragraph": "二、初始胰岛素治疗方案的制定",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、初始胰岛素治疗方案的制定",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T70",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "2. Development of an initial insulin therapy plan"
        }
      ],
      "paragraph_en": "2. Development of an initial insulin therapy plan"
    },
    {
      "paragraph_id": "10",
      "paragraph": "临床医师在制定胰岛素方案、剂量调整和设定糖尿病血糖控制目标时，除考虑病理生理因素外，还必须考虑社会经济因素，并统筹考虑安全性、可行性和科学性，制定个体化的血糖控制目标和起始治疗方案。同时，在治疗过程中，应及时进行临床评价，进行适当调整。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床医师在制定胰岛素方案、剂量调整和设定糖尿病血糖控制目标时，除考虑病理生理因素外，还必须考虑社会经济因素，并统筹考虑安全性、可行性和科学性，制定个体化的血糖控制目标和起始治疗方案。",
          "start_idx": 0,
          "end_idx": 91,
          "entities": [
            {
              "entity_id": "T71",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T72",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T73",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T74",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 77,
              "end_idx": 79,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R25",
              "head_entity_id": "T71",
              "tail_entity_id": "T72"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R26",
              "head_entity_id": "T73",
              "tail_entity_id": "T72"
            }
          ],
          "sentence_en": "When formulating insulin regimens, adjusting doses, and setting blood sugar control targets for diabetes, clinicians must consider not only pathophysiological factors but also socioeconomic factors, and comprehensively consider safety, feasibility, and scientificity to formulate individualized blood sugar control targets and initial treatment plans."
        },
        {
          "sentence_id": "1",
          "sentence": "同时，在治疗过程中，应及时进行临床评价，进行适当调整。",
          "start_idx": 91,
          "end_idx": 118,
          "entities": [],
          "relations": [],
          "sentence_en": "At the same time, clinical evaluation should be carried out in a timely manner and appropriate adjustments should be made during the treatment process."
        }
      ],
      "paragraph_en": "When formulating insulin regimens, adjusting doses, and setting diabetes blood sugar control targets, clinicians must consider not only pathophysiological factors, but also socioeconomic factors, and comprehensively consider safety, feasibility, and scientificity to formulate individualized blood sugar control targets and initial treatment plans. At the same time, clinical evaluations should be conducted in a timely manner during treatment and appropriate adjustments should be made."
    },
    {
      "paragraph_id": "11",
      "paragraph": "1.制定个体化的治疗目标：(1)长期血糖控制目标：一般而言，以反映最近2~3个月血糖控制情况的HbA1c为主要目标，兼顾空腹和餐后血糖达标(具体可参照《中国成人2型糖尿病Hbh1c控制目标的专家共识》，表3)。(2)短期血糖控制目标：一般住院患者，降糖治疗以即时血糖达标为主要目标。一般推荐7.8~10mmol/L(140~180mg/d1)为宜。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.制定个体化的治疗目标：(1)长期血糖控制目标：一般而言，以反映最近2~3个月血糖控制情况的HbA1c为主要目标，兼顾空腹和餐后血糖达标(具体可参照《中国成人2型糖尿病Hbh1c控制目标的专家共识》，表3)。",
          "start_idx": 0,
          "end_idx": 105,
          "entities": [
            {
              "entity_id": "T75",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T76",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T77",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 52,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T78",
              "entity": "空腹和餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 67,
              "entity_en": "Fasting and postprandial blood sugar"
            },
            {
              "entity_id": "T79",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 67,
              "end_idx": 69,
              "entity_en": "Meet the Standard"
            },
            {
              "entity_id": "T80",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 80,
              "end_idx": 85,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T81",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 80,
              "end_idx": 82,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T82",
              "entity": "Hbh1c",
              "entity_type": "Test_items",
              "start_idx": 85,
              "end_idx": 90,
              "entity_en": "HbH1c"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R27",
              "head_entity_id": "T81",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R28",
              "head_entity_id": "T82",
              "tail_entity_id": "T80"
            }
          ],
          "sentence_en": "1. Develop individualized treatment goals: (1) Long-term blood sugar control goals: Generally speaking, the HbA1c, which reflects the blood sugar control status in the past 2 to 3 months, is the main goal, while taking into account fasting and postprandial blood sugar standards (for details, please refer to the \"Expert Consensus on HbA1c Control Goals for Chinese Adults with Type 2 Diabetes\", Table 3)."
        },
        {
          "sentence_id": "1",
          "sentence": "(2)短期血糖控制目标：一般住院患者，降糖治疗以即时血糖达标为主要目标。",
          "start_idx": 105,
          "end_idx": 141,
          "entities": [
            {
              "entity_id": "T83",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T84",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T85",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "Meet the Standard"
            }
          ],
          "relations": [],
          "sentence_en": "(2) Short-term blood sugar control target: For general hospitalized patients, the main goal of glucose-lowering treatment is to achieve immediate blood sugar control targets."
        },
        {
          "sentence_id": "2",
          "sentence": "一般推荐7.8~10mmol/L(140~180mg/d1)为宜。",
          "start_idx": 141,
          "end_idx": 174,
          "entities": [
            {
              "entity_id": "T86",
              "entity": "7.8~10mmol/L(140~180mg/d1)",
              "entity_type": "Test_Value",
              "start_idx": 4,
              "end_idx": 30,
              "entity_en": "7.8~10mmol/L (140~180mg/d1)"
            }
          ],
          "relations": [],
          "sentence_en": "The general recommendation is 7.8~10mmol/L (140~180mg/d1)."
        }
      ],
      "paragraph_en": "1. Develop individualized treatment goals: (1) Long-term blood sugar control goals: Generally speaking, the HbA1c, which reflects the blood sugar control status in the past 2 to 3 months, is the main goal, taking into account fasting and postprandial blood sugar targets (for details, please refer to the \"Expert Consensus on HbA1c Control Targets for Chinese Adults with Type 2 Diabetes\", Table 3). (2) Short-term blood sugar control goals: For general inpatients, the main goal of hypoglycemic treatment is to achieve immediate blood sugar targets. Generally, 7.8~10mmol/L (140~180mg/d1) is recommended."
    },
    {
      "paragraph_id": "12",
      "paragraph": "2.各种治疗方案的特点：目前临床中常见的胰岛素治疗方案有1天1次或2次基础胰岛素联合口服药、1天2次预混胰岛素方案、基础+餐时胰岛素方案。各种方案适用于不同的临床情况(根据患者的治疗意愿、能力、生活方式和血糖状况做出选择)，具体详见表4。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.各种治疗方案的特点：目前临床中常见的胰岛素治疗方案有1天1次或2次基础胰岛素联合口服药、1天2次预混胰岛素方案、基础+餐时胰岛素方案。",
          "start_idx": 0,
          "end_idx": 69,
          "entities": [
            {
              "entity_id": "T87",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T88",
              "entity": "1天1次或2次",
              "entity_type": "Frequency",
              "start_idx": 28,
              "end_idx": 35,
              "entity_en": "1 or 2 times a day"
            },
            {
              "entity_id": "T89",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 40,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T90",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "oral"
            },
            {
              "entity_id": "T91",
              "entity": "1天2次",
              "entity_type": "Frequency",
              "start_idx": 46,
              "end_idx": 50,
              "entity_en": "2 times a day"
            },
            {
              "entity_id": "T92",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 55,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T93",
              "entity": "基础+餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 66,
              "entity_en": "Basal + mealtime insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R29",
              "head_entity_id": "T88",
              "tail_entity_id": "T89"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R30",
              "head_entity_id": "T91",
              "tail_entity_id": "T92"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R31",
              "head_entity_id": "T91",
              "tail_entity_id": "T93"
            }
          ],
          "sentence_en": "2. Characteristics of various treatment plans: Currently, the common insulin treatment plans in clinical practice include basal insulin once or twice a day combined with oral medication, premixed insulin twice a day, and basal + mealtime insulin."
        },
        {
          "sentence_id": "1",
          "sentence": "各种方案适用于不同的临床情况(根据患者的治疗意愿、能力、生活方式和血糖状况做出选择)，具体详见表4。",
          "start_idx": 69,
          "end_idx": 119,
          "entities": [
            {
              "entity_id": "T94",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Various regimens are suitable for different clinical situations (selection is based on the patient's treatment willingness, ability, lifestyle and blood sugar status), see Table 4 for details."
        }
      ],
      "paragraph_en": "2. Characteristics of various treatment plans: Common insulin treatment plans in clinical practice include once or twice a day basal insulin combined with oral medication, twice a day premixed insulin plan, and basal + mealtime insulin plan. Various plans are suitable for different clinical situations (based on the patient's treatment willingness, ability, lifestyle and blood sugar status), see Table 4 for details."
    },
    {
      "paragraph_id": "13",
      "paragraph": "3.不同治疗方案的选择：目前尚无循证医学证据证实何种胰岛素起始治疗方案更优，各权威学术组织推荐的胰岛素启动治疗方案不尽相同。多数国家和地区[美国糖尿病学会(ADA)/欧洲糖尿病研究协会(EASD)联合共识、中国台湾糖尿病临床照护指引、英国国家健康与临床优化研究所(ICE)临床指南、国际糖尿病联盟(IDF)欧洲指南]推荐起始使用基础胰岛素。若血糖控制不达标，可加用餐时胰岛素。美国临床内分泌医师协会(AACE)/美国内分泌学院(ACE)专家共识推荐基础胰岛素、预混胰岛素、基础-餐时胰岛素或餐时胰岛素1日多次注射、餐时胰岛素加二甲双胍这4种胰岛素方案中任一种均可作为起始治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.不同治疗方案的选择：目前尚无循证医学证据证实何种胰岛素起始治疗方案更优，各权威学术组织推荐的胰岛素启动治疗方案不尽相同。多数国家和地区[美国糖尿病学会(ADA)/欧洲糖尿病研究协会(EASD)联合共识、中国台湾糖尿病临床照护指引、英国国家健康与临床优化研究所(ICE)临床指南、国际糖尿病联盟(IDF)欧洲指南]推荐起始使用基础胰岛素。若血糖控制不达标，可加用餐时胰岛素。美国临床内分泌医师协会(AACE)/美国内分泌学院(ACE)专家共识推荐基础胰岛素、预混胰岛素、基础-餐时胰岛素或餐时胰岛素1日多次注射、餐时胰岛素加二甲双胍这4种胰岛素方案中任一种均可作为起始治疗。",
          "start_idx": 0,
          "end_idx": 288,
          "entities": [
            {
              "entity_id": "T95",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 29,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T96",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T97",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 75,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T98",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 88,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T99",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 110,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T100",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 143,
              "end_idx": 146,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T101",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 166,
              "end_idx": 169,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T102",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 171,
              "end_idx": 173,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T103",
              "entity": "控制不达标",
              "entity_type": "Test_Value",
              "start_idx": 173,
              "end_idx": 178,
              "entity_en": "Control not up to standard"
            },
            {
              "entity_id": "T104",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 187,
              "entity_en": "Mealtime insulin"
            },
            {
              "entity_id": "T105",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 224,
              "end_idx": 229,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T106",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 230,
              "end_idx": 235,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T107",
              "entity": "基础-餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 236,
              "end_idx": 244,
              "entity_en": "Basal-meal insulin"
            },
            {
              "entity_id": "T108",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 245,
              "end_idx": 250,
              "entity_en": "Mealtime insulin"
            },
            {
              "entity_id": "T109",
              "entity": "1日多次",
              "entity_type": "Frequency",
              "start_idx": 250,
              "end_idx": 254,
              "entity_en": "Multiple times a day"
            },
            {
              "entity_id": "T110",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 254,
              "end_idx": 256,
              "entity_en": "injection"
            },
            {
              "entity_id": "T111",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 257,
              "end_idx": 262,
              "entity_en": "Mealtime insulin"
            },
            {
              "entity_id": "T112",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 263,
              "end_idx": 267,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T113",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 270,
              "end_idx": 273,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R32",
              "head_entity_id": "T109",
              "tail_entity_id": "T105"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R33",
              "head_entity_id": "T110",
              "tail_entity_id": "T105"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R34",
              "head_entity_id": "T109",
              "tail_entity_id": "T106"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R35",
              "head_entity_id": "T110",
              "tail_entity_id": "T106"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R36",
              "head_entity_id": "T109",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R37",
              "head_entity_id": "T110",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R38",
              "head_entity_id": "T109",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R39",
              "head_entity_id": "T110",
              "tail_entity_id": "T108"
            }
          ],
          "sentence_en": "3. Choice of different treatment plans: There is currently no evidence-based medical evidence to confirm which insulin starting treatment plan is better, and the insulin starting treatment plans recommended by various authoritative academic organizations are not the same. Most countries and regions [Joint consensus of the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD), Taiwan Diabetes Clinical Care Guidelines, UK National Institute for Health and Care Excellence (ICE) Clinical Guidelines, International Diabetes Federation (IDF) European Guidelines] recommend starting with basal insulin. If blood sugar control is not up to standard, mealtime insulin can be added. The American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) expert consensus recommends that any of the four insulin plans, basal insulin, premixed insulin, basal-mealtime insulin or multiple injections of mealtime insulin per day, and mealtime insulin plus metformin, can be used as initial treatment."
        }
      ],
      "paragraph_en": "3. Choice of different treatment plans: There is currently no evidence-based medical evidence to confirm which insulin starting treatment plan is better, and the insulin starting treatment plans recommended by various authoritative academic organizations are not the same. Most countries and regions [Joint consensus of the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD), Taiwan Diabetes Clinical Care Guidelines, UK National Institute for Health and Care Excellence (ICE) Clinical Guidelines, International Diabetes Federation (IDF) European Guidelines] recommend starting with basal insulin. If blood sugar control is not up to standard, mealtime insulin can be added. The American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) expert consensus recommends that any of the four insulin regimens, basal insulin, premixed insulin, basal-mealtime insulin or multiple injections of mealtime insulin per day, and mealtime insulin plus metformin, can be used as initial treatment."
    },
    {
      "paragraph_id": "14",
      "paragraph": "总体而言，预混胰岛素治疗达标率更高，基础胰岛素治疗低血糖发生率相对较低。亚裔糖尿病患者中以餐后血糖增高更常见，餐后血糖在血糖控制中的作用尤为重要。中国2型糖尿病防治指南(2010年版)指出，每日1次基础胰岛素或每日1~2次预混胰岛素均可作为胰岛素起始治疗方案，如基础胰岛素或预混胰岛素与口服药物联合治疗控制血糖不达标则应将治疗方案调整为多次胰岛素治疗(基础胰岛素加餐时胰岛素或每日3次预混胰岛素。图1)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "总体而言，预混胰岛素治疗达标率更高，基础胰岛素治疗低血糖发生率相对较低。亚裔糖尿病患者中以餐后血糖增高更常见，餐后血糖在血糖控制中的作用尤为重要。中国2型糖尿病防治指南(2010年版)指出，每日1次基础胰岛素或每日1~2次预混胰岛素均可作为胰岛素起始治疗方案，如基础胰岛素或预混胰岛素与口服药物联合治疗控制血糖不达标则应将治疗方案调整为多次胰岛素治疗(基础胰岛素加餐时胰岛素或每日3次预混胰岛素。",
          "start_idx": 0,
          "end_idx": 198,
          "entities": [
            {
              "entity_id": "T114",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T115",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T116",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T117",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 41,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T118",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T119",
              "entity": "增高",
              "entity_type": "Test_Value",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "Increase"
            },
            {
              "entity_id": "T120",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T121",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 62,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T122",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 80,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T123",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 75,
              "end_idx": 77,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T124",
              "entity": "每日1次",
              "entity_type": "Frequency",
              "start_idx": 95,
              "end_idx": 99,
              "entity_en": "1 time per day"
            },
            {
              "entity_id": "T125",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 99,
              "end_idx": 104,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T126",
              "entity": "每日1~2次",
              "entity_type": "Frequency",
              "start_idx": 105,
              "end_idx": 111,
              "entity_en": "1-2 times a day"
            },
            {
              "entity_id": "T127",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 116,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T128",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 123,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T129",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 131,
              "end_idx": 136,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T130",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 142,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T131",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 143,
              "end_idx": 145,
              "entity_en": "oral"
            },
            {
              "entity_id": "T132",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 153,
              "end_idx": 155,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T133",
              "entity": "不达标",
              "entity_type": "Test_Value",
              "start_idx": 155,
              "end_idx": 158,
              "entity_en": "Not up to standard"
            },
            {
              "entity_id": "T134",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 170,
              "end_idx": 173,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T135",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 176,
              "end_idx": 181,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T136",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 187,
              "entity_en": "Mealtime insulin"
            },
            {
              "entity_id": "T137",
              "entity": "每日3次",
              "entity_type": "Frequency",
              "start_idx": 188,
              "end_idx": 192,
              "entity_en": "3 times a day"
            },
            {
              "entity_id": "T138",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 192,
              "end_idx": 197,
              "entity_en": "Premixed insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R40",
              "head_entity_id": "T116",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R41",
              "head_entity_id": "T118",
              "tail_entity_id": "T117"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R42",
              "head_entity_id": "T123",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R43",
              "head_entity_id": "T125",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R44",
              "head_entity_id": "T127",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R45",
              "head_entity_id": "T128",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R46",
              "head_entity_id": "T124",
              "tail_entity_id": "T125"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R47",
              "head_entity_id": "T126",
              "tail_entity_id": "T127"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R48",
              "head_entity_id": "T137",
              "tail_entity_id": "T138"
            }
          ],
          "sentence_en": "In general, the target achievement rate of premixed insulin treatment is higher, and the incidence of hypoglycemia in basal insulin treatment is relatively low. Postprandial blood sugar is more common in Asian diabetic patients, and the role of postprandial blood sugar in blood sugar control is particularly important. The Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2010 Edition) point out that basal insulin once a day or premixed insulin once or twice a day can be used as the initial insulin treatment plan. If basal insulin or premixed insulin combined with oral medications cannot control blood sugar, the treatment plan should be adjusted to multiple insulin treatments (basal insulin plus mealtime insulin or premixed insulin three times a day)."
        },
        {
          "sentence_id": "1",
          "sentence": "图1)。",
          "start_idx": 198,
          "end_idx": 202,
          "entities": [],
          "relations": [],
          "sentence_en": "Figure 1)."
        }
      ],
      "paragraph_en": "In general, the target achievement rate of premixed insulin treatment is higher, and the incidence of hypoglycemia in basal insulin treatment is relatively low. Postprandial blood glucose is more common in Asian diabetic patients, and the role of postprandial blood glucose in blood glucose control is particularly important. The Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2010 Edition) point out that basal insulin once a day or premixed insulin once or twice a day can be used as the initial insulin treatment plan. If basal insulin or premixed insulin combined with oral medications cannot control blood glucose to target, the treatment plan should be adjusted to multiple insulin treatments (basal insulin plus mealtime insulin or premixed insulin three times a day. Figure 1)."
    },
    {
      "paragraph_id": "15",
      "paragraph": "三、不同类别胰岛素的选择",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "三、不同类别胰岛素的选择",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [
            {
              "entity_id": "T139",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "3. Choice of different types of insulin"
        }
      ],
      "paragraph_en": "3. Choice of different types of insulin"
    },
    {
      "paragraph_id": "17",
      "paragraph": "药物经济学已经成为评价临床治疗方案的重要手段之一。在选择2型糖尿病治疗方案时，应综合考虑控制医疗费用、患者病情及其支付能力等多方面因素。作为发展中国家，我国医疗资源仍相对匮乏，且糖尿病患者人数众多且增长迅猛，在为2型糖尿病制定胰岛素治疗方案时需考虑以上诸多因素。人胰岛素经济、安全、有效，在2型糖尿病治疗中发挥重要的作用。正是基于成本和效益比基础上，《国家基本医疗保险、工伤保险和生育保险药品目录(2009年版)》亦对胰岛素的选择做出规定(表5)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "药物经济学已经成为评价临床治疗方案的重要手段之一。在选择2型糖尿病治疗方案时，应综合考虑控制医疗费用、患者病情及其支付能力等多方面因素。作为发展中国家，我国医疗资源仍相对匮乏，且糖尿病患者人数众多且增长迅猛，在为2型糖尿病制定胰岛素治疗方案时需考虑以上诸多因素。",
          "start_idx": 0,
          "end_idx": 131,
          "entities": [
            {
              "entity_id": "T140",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 33,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T141",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T142",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 92,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T143",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 111,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T144",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 106,
              "end_idx": 108,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T145",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 116,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R49",
              "head_entity_id": "T141",
              "tail_entity_id": "T140"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R50",
              "head_entity_id": "T144",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R51",
              "head_entity_id": "T145",
              "tail_entity_id": "T143"
            }
          ],
          "sentence_en": "Pharmacoeconomics has become one of the important means of evaluating clinical treatment plans. When choosing a treatment plan for type 2 diabetes, multiple factors should be considered, including controlling medical expenses, the patient's condition and their ability to pay. As a developing country, my country's medical resources are still relatively scarce, and the number of diabetes patients is large and growing rapidly. The above factors need to be considered when formulating insulin treatment plans for type 2 diabetes."
        },
        {
          "sentence_id": "1",
          "sentence": "人胰岛素经济、安全、有效，在2型糖尿病治疗中发挥重要的作用。",
          "start_idx": 131,
          "end_idx": 161,
          "entities": [
            {
              "entity_id": "T146",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T147",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T148",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Human insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R52",
              "head_entity_id": "T147",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R53",
              "head_entity_id": "T148",
              "tail_entity_id": "T146"
            }
          ],
          "sentence_en": "Human insulin is economical, safe and effective, and plays an important role in the treatment of type 2 diabetes."
        },
        {
          "sentence_id": "2",
          "sentence": "正是基于成本和效益比基础上，《国家基本医疗保险、工伤保险和生育保险药品目录(2009年版)》亦对胰岛素的选择做出规定(表5)。",
          "start_idx": 161,
          "end_idx": 224,
          "entities": [
            {
              "entity_id": "T149",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "It is based on the cost-benefit ratio that the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug List (2009 Edition) also stipulates the choice of insulin (Table 5)."
        }
      ],
      "paragraph_en": "Pharmacoeconomics has become one of the important means to evaluate clinical treatment plans. When choosing a treatment plan for type 2 diabetes, multiple factors should be considered, such as controlling medical expenses, the patient's condition and their ability to pay. As a developing country, my country's medical resources are still relatively scarce, and the number of diabetes patients is large and growing rapidly. The above factors need to be considered when formulating insulin treatment plans for type 2 diabetes. Human insulin is economical, safe and effective, and plays an important role in the treatment of type 2 diabetes. It is based on the cost-effectiveness ratio that the \"National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalog (2009 Edition)\" also stipulates the choice of insulin (Table 5)."
    },
    {
      "paragraph_id": "16",
      "paragraph": "目前用于临床的胰岛素包括动物胰岛素、人胰岛素和胰岛素类似物。由于潜在免疫原性等问题，动物胰岛素在大多数地区使用逐渐减少，人胰岛素和胰岛素类似物使用逐渐增多。人胰岛素与人体自身分泌的胰岛素结构完全相同，胰岛素类似物通过改变胰岛素结构而改变胰岛素药代动力学特性。短期研究表明，胰岛素类似物与人胰岛素相比，控制HbA1c的能力相似，但使用更方便，在减少低血糖发生的潜在危险方面胰岛素类似物优于人胰岛素，这一优势主要表现在1型糖尿病患者。目前尚缺乏胰岛素类似物对患者长期终点事件，如死亡率、糖尿病相关微血管和大血管并发症等方面的证据。多项meta分析及临床研究显示，在2型糖尿病患者中，胰岛素类似物在HbA1c达标率、胰岛素剂量、体重、日问低血糖、严重低血糖和不良反应方面与人胰岛素相当，长效胰岛素类似物对夜间低血糖的改善优于NPH。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前用于临床的胰岛素包括动物胰岛素、人胰岛素和胰岛素类似物。由于潜在免疫原性等问题，动物胰岛素在大多数地区使用逐渐减少，人胰岛素和胰岛素类似物使用逐渐增多。人胰岛素与人体自身分泌的胰岛素结构完全相同，胰岛素类似物通过改变胰岛素结构而改变胰岛素药代动力学特性。短期研究表明，胰岛素类似物与人胰岛素相比，控制HbA1c的能力相似，但使用更方便，在减少低血糖发生的潜在危险方面胰岛素类似物优于人胰岛素，这一优势主要表现在1型糖尿病患者。目前尚缺乏胰岛素类似物对患者长期终点事件，如死亡率、糖尿病相关微血管和大血管并发症等方面的证据。多项meta分析及临床研究显示，在2型糖尿病患者中，胰岛素类似物在HbA1c达标率、胰岛素剂量、体重、日问低血糖、严重低血糖和不良反应方面与人胰岛素相当，长效胰岛素类似物对夜间低血糖的改善优于NPH。",
          "start_idx": 0,
          "end_idx": 363,
          "entities": [
            {
              "entity_id": "T150",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T151",
              "entity": "动物胰岛素",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Animal insulin"
            },
            {
              "entity_id": "T152",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Human insulin"
            },
            {
              "entity_id": "T153",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 29,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T154",
              "entity": "动物胰岛素",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 47,
              "entity_en": "Animal insulin"
            },
            {
              "entity_id": "T155",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Human insulin"
            },
            {
              "entity_id": "T156",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 71,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T157",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "Human insulin"
            },
            {
              "entity_id": "T158",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 106,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T159",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 121,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T160",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 136,
              "end_idx": 142,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T161",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 143,
              "end_idx": 147,
              "entity_en": "Human insulin"
            },
            {
              "entity_id": "T162",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 152,
              "end_idx": 157,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T163",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 173,
              "end_idx": 176,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T164",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 185,
              "end_idx": 191,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T165",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 193,
              "end_idx": 197,
              "entity_en": "Human insulin"
            },
            {
              "entity_id": "T166",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 207,
              "end_idx": 212,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T167",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 207,
              "end_idx": 209,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T168",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 220,
              "end_idx": 226,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T169",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 241,
              "end_idx": 244,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T170",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 246,
              "end_idx": 249,
              "entity_en": "Microvascular"
            },
            {
              "entity_id": "T171",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 250,
              "end_idx": 253,
              "entity_en": "Large blood vessels"
            },
            {
              "entity_id": "T172",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 280,
              "end_idx": 285,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T173",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 280,
              "end_idx": 282,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T174",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 289,
              "end_idx": 295,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T175",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 296,
              "end_idx": 301,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T176",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 305,
              "end_idx": 308,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T177",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 316,
              "end_idx": 319,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T178",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 320,
              "end_idx": 322,
              "entity_en": "serious"
            },
            {
              "entity_id": "T179",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 322,
              "end_idx": 325,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T180",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 333,
              "end_idx": 337,
              "entity_en": "Human insulin"
            },
            {
              "entity_id": "T181",
              "entity": "长效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 340,
              "end_idx": 348,
              "entity_en": "Long-acting insulin analogs"
            },
            {
              "entity_id": "T182",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 351,
              "end_idx": 354,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T183",
              "entity": "NPH",
              "entity_type": "Drug",
              "start_idx": 359,
              "end_idx": 362,
              "entity_en": "NPH"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R54",
              "head_entity_id": "T163",
              "tail_entity_id": "T164"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R55",
              "head_entity_id": "T163",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R56",
              "head_entity_id": "T164",
              "tail_entity_id": "T166"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R57",
              "head_entity_id": "T165",
              "tail_entity_id": "T166"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R58",
              "head_entity_id": "T167",
              "tail_entity_id": "T166"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R59",
              "head_entity_id": "T168",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R60",
              "head_entity_id": "T170",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R61",
              "head_entity_id": "T171",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R62",
              "head_entity_id": "T173",
              "tail_entity_id": "T172"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R63",
              "head_entity_id": "T174",
              "tail_entity_id": "T172"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R64",
              "head_entity_id": "T180",
              "tail_entity_id": "T172"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R65",
              "head_entity_id": "T181",
              "tail_entity_id": "T172"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R66",
              "head_entity_id": "T183",
              "tail_entity_id": "T172"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R67",
              "head_entity_id": "T175",
              "tail_entity_id": "T172"
            }
          ],
          "sentence_en": "The insulin currently used in clinical practice includes animal insulin, human insulin and insulin analogs. Due to potential immunogenicity and other issues, the use of animal insulin has gradually decreased in most areas, while the use of human insulin and insulin analogs has gradually increased. Human insulin has exactly the same structure as the insulin secreted by the human body itself. Insulin analogs change the pharmacokinetic properties of insulin by changing the structure of insulin. Short-term studies have shown that compared with human insulin, insulin analogs have similar ability to control HbA1c, but are more convenient to use. Insulin analogs are superior to human insulin in reducing the potential risk of hypoglycemia, and this advantage is mainly manifested in patients with type 1 diabetes. At present, there is a lack of evidence on the effects of insulin analogs on long-term endpoints of patients, such as mortality, diabetes-related microvascular and macrovascular complications, etc. Multiple meta-analyses and clinical studies have shown that in patients with type 2 diabetes, insulin analogs are comparable to human insulin in terms of HbA1c compliance rate, insulin dose, body weight, daily hypoglycemia, severe hypoglycemia and adverse reactions, and long-acting insulin analogs are better than NPH in improving nocturnal hypoglycemia."
        }
      ],
      "paragraph_en": "The insulin currently used in clinical practice includes animal insulin, human insulin and insulin analogs. Due to potential immunogenicity and other issues, the use of animal insulin has gradually decreased in most areas, while the use of human insulin and insulin analogs has gradually increased. Human insulin has exactly the same structure as the insulin secreted by the human body itself. Insulin analogs change the pharmacokinetic properties of insulin by changing the structure of insulin. Short-term studies have shown that compared with human insulin, insulin analogs have similar ability to control HbA1c, but are more convenient to use. Insulin analogs are superior to human insulin in reducing the potential risk of hypoglycemia, and this advantage is mainly manifested in patients with type 1 diabetes. At present, there is a lack of evidence on the effects of insulin analogs on long-term endpoints of patients, such as mortality, diabetes-related microvascular and macrovascular complications, etc. Multiple meta-analyses and clinical studies have shown that in patients with type 2 diabetes, insulin analogs are comparable to human insulin in terms of HbA1c compliance rate, insulin dose, body weight, daily hypoglycemia, severe hypoglycemia and adverse reactions, and long-acting insulin analogs are better than NPH in improving nocturnal hypoglycemia."
    },
    {
      "paragraph_id": "18",
      "paragraph": "四、胰岛素应用中应注意的问题",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "四、胰岛素应用中应注意的问题",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T184",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "IV. Issues that should be noted in the use of insulin"
        }
      ],
      "paragraph_en": "IV. Issues that should be noted in the use of insulin"
    },
    {
      "paragraph_id": "19",
      "paragraph": "1.在积极使用胰岛素的同时，应合理使用胰岛素，避免过度应用。对于肥胖(体重指数>28kg/m2)的患者，应在口服药充分治疗的基础上起始胰岛素治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.在积极使用胰岛素的同时，应合理使用胰岛素，避免过度应用。对于肥胖(体重指数>28kg/m2)的患者，应在口服药充分治疗的基础上起始胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 73,
          "entities": [
            {
              "entity_id": "T185",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T186",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T187",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T188",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "oral"
            },
            {
              "entity_id": "T189",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 70,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R68",
              "head_entity_id": "T189",
              "tail_entity_id": "T187"
            }
          ],
          "sentence_en": "1. While actively using insulin, insulin should be used rationally to avoid overuse. For obese patients (BMI>28kg/m2), insulin treatment should be initiated on the basis of adequate oral medication treatment."
        }
      ],
      "paragraph_en": "1. While actively using insulin, insulin should be used rationally to avoid overuse. For obese patients (BMI>28kg/m2), insulin treatment should be initiated on the basis of adequate oral medication treatment."
    },
    {
      "paragraph_id": "20",
      "paragraph": "2.合理的联合用药，避免药物不良反应的产生和叠加。单独使用胰岛素的主要不良反应是低血糖和体重增加。推荐采用胰岛素/口服药联合方案，以增加降糖疗效，同时减少低血糖和体重增加的不良反应。二甲双胍与胰岛素联用可减少体重增加，减少外源性胰岛素用量。α-葡萄糖苷酶抑制剂与胰岛素联用在有效改善血糖的同时，减少胰岛素使用剂量，减少体重增加的幅度和趋势。因此，在无禁忌证的2型糖尿病患者中均可采用二甲双胍或α糖苷酶抑制剂与胰岛素联用。促泌剂可发生低血糖和体重增加的不良反应，因此，除基础胰岛素外，不建议胰岛素和促泌剂联合使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.合理的联合用药，避免药物不良反应的产生和叠加。单独使用胰岛素的主要不良反应是低血糖和体重增加。推荐采用胰岛素/口服药联合方案，以增加降糖疗效，同时减少低血糖和体重增加的不良反应。二甲双胍与胰岛素联用可减少体重增加，减少外源性胰岛素用量。α-葡萄糖苷酶抑制剂与胰岛素联用在有效改善血糖的同时，减少胰岛素使用剂量，减少体重增加的幅度和趋势。因此，在无禁忌证的2型糖尿病患者中均可采用二甲双胍或α糖苷酶抑制剂与胰岛素联用。",
          "start_idx": 0,
          "end_idx": 210,
          "entities": [
            {
              "entity_id": "T190",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 32,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T191",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 40,
              "end_idx": 43,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T192",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 44,
              "end_idx": 48,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T193",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 56,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T194",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 57,
              "end_idx": 59,
              "entity_en": "oral"
            },
            {
              "entity_id": "T195",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 77,
              "end_idx": 80,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T196",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 81,
              "end_idx": 85,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T197",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 91,
              "end_idx": 95,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T198",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 96,
              "end_idx": 99,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T199",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 104,
              "end_idx": 108,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T200",
              "entity": "外源性胰岛素",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 117,
              "entity_en": "Exogenous insulin"
            },
            {
              "entity_id": "T201",
              "entity": "α-葡萄糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 130,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T202",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 131,
              "end_idx": 134,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T203",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 141,
              "end_idx": 143,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T204",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 149,
              "end_idx": 152,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T205",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 159,
              "end_idx": 163,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T206",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 179,
              "end_idx": 184,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T207",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 179,
              "end_idx": 181,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T208",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 191,
              "end_idx": 195,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T209",
              "entity": "α糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 196,
              "end_idx": 203,
              "entity_en": "Alpha-glucosidase inhibitors"
            },
            {
              "entity_id": "T210",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 204,
              "end_idx": 207,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R69",
              "head_entity_id": "T191",
              "tail_entity_id": "T190"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R70",
              "head_entity_id": "T192",
              "tail_entity_id": "T190"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R71",
              "head_entity_id": "T199",
              "tail_entity_id": "T197"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R72",
              "head_entity_id": "T199",
              "tail_entity_id": "T198"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R73",
              "head_entity_id": "T205",
              "tail_entity_id": "T204"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R74",
              "head_entity_id": "T207",
              "tail_entity_id": "T206"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R75",
              "head_entity_id": "T208",
              "tail_entity_id": "T206"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R76",
              "head_entity_id": "T209",
              "tail_entity_id": "T206"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R77",
              "head_entity_id": "T210",
              "tail_entity_id": "T206"
            }
          ],
          "sentence_en": "2. Reasonable combination of drugs to avoid the occurrence and superposition of adverse drug reactions. The main adverse reactions of using insulin alone are hypoglycemia and weight gain. It is recommended to use a combination of insulin/oral medication to increase the hypoglycemic effect while reducing the adverse reactions of hypoglycemia and weight gain. The combination of metformin and insulin can reduce weight gain and reduce the amount of exogenous insulin. The combination of α-glucosidase inhibitors and insulin can effectively improve blood sugar while reducing the dosage of insulin and the magnitude and trend of weight gain. Therefore, metformin or α-glucosidase inhibitors can be used in combination with insulin in patients with type 2 diabetes without contraindications."
        },
        {
          "sentence_id": "1",
          "sentence": "促泌剂可发生低血糖和体重增加的不良反应，因此，除基础胰岛素外，不建议胰岛素和促泌剂联合使用。",
          "start_idx": 210,
          "end_idx": 256,
          "entities": [
            {
              "entity_id": "T211",
              "entity": "促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "Secretagogues"
            },
            {
              "entity_id": "T212",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T213",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T214",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T215",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T216",
              "entity": "促泌剂",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 41,
              "entity_en": "Secretagogues"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R78",
              "head_entity_id": "T212",
              "tail_entity_id": "T211"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R79",
              "head_entity_id": "T213",
              "tail_entity_id": "T211"
            }
          ],
          "sentence_en": "Secretagogues can cause adverse reactions such as hypoglycemia and weight gain; therefore, except for basal insulin, the combined use of insulin and secretagogues is not recommended."
        }
      ],
      "paragraph_en": "2. Reasonable combination of drugs to avoid the occurrence and superposition of adverse drug reactions. The main adverse reactions of using insulin alone are hypoglycemia and weight gain. It is recommended to use a combination of insulin/oral medication to increase the hypoglycemic effect while reducing the adverse reactions of hypoglycemia and weight gain. The combination of metformin and insulin can reduce weight gain and reduce the amount of exogenous insulin. The combination of α-glucosidase inhibitors and insulin can effectively improve blood sugar while reducing the dosage of insulin and the magnitude and trend of weight gain. Therefore, metformin or α-glucosidase inhibitors can be used in combination with insulin in patients with type 2 diabetes without contraindications. Secretagogues can cause adverse reactions of hypoglycemia and weight gain. Therefore, except for basal insulin, the combined use of insulin and secretagogues is not recommended."
    },
    {
      "paragraph_id": "21",
      "paragraph": "3.对已合并心脑血管疾病或危险因素的2型糖尿病患者，或老年糖尿病患者，过于激进的降糖治疗策略可能产生潜在的风险，进而抵消或掩盖其潜在的心血管获益。由于脑组织代谢的特殊性，卒中患者对低血糖的耐受性更低，在使用胰岛素时，应采取相对宽松的降糖治疗策略与目标值，避免低血糖的发生。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.对已合并心脑血管疾病或危险因素的2型糖尿病患者，或老年糖尿病患者，过于激进的降糖治疗策略可能产生潜在的风险，进而抵消或掩盖其潜在的心血管获益。由于脑组织代谢的特殊性，卒中患者对低血糖的耐受性更低，在使用胰岛素时，应采取相对宽松的降糖治疗策略与目标值，避免低血糖的发生。",
          "start_idx": 0,
          "end_idx": 136,
          "entities": [
            {
              "entity_id": "T217",
              "entity": "心脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 12,
              "entity_en": "Cardiovascular and cerebrovascular diseases"
            },
            {
              "entity_id": "T218",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T219",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T220",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T221",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 32,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T222",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 87,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T223",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 90,
              "end_idx": 93,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T224",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 106,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T225",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 129,
              "end_idx": 132,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R80",
              "head_entity_id": "T218",
              "tail_entity_id": "T217"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R81",
              "head_entity_id": "T220",
              "tail_entity_id": "T219"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R82",
              "head_entity_id": "T224",
              "tail_entity_id": "T222"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R83",
              "head_entity_id": "T224",
              "tail_entity_id": "T223"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R84",
              "head_entity_id": "T225",
              "tail_entity_id": "T224"
            }
          ],
          "sentence_en": "3. For patients with type 2 diabetes who have cardiovascular and cerebrovascular diseases or risk factors, or elderly patients with diabetes, overly aggressive glucose-lowering treatment strategies may pose potential risks, thereby offsetting or masking their potential cardiovascular benefits. Due to the particularity of brain tissue metabolism, stroke patients have a lower tolerance to hypoglycemia. When using insulin, a relatively loose glucose-lowering treatment strategy and target value should be adopted to avoid the occurrence of hypoglycemia."
        }
      ],
      "paragraph_en": "3. For patients with type 2 diabetes who have cardiovascular and cerebrovascular diseases or risk factors, or elderly patients with diabetes, overly aggressive glucose-lowering treatment strategies may pose potential risks, thereby offsetting or masking their potential cardiovascular benefits. Due to the particularity of brain tissue metabolism, stroke patients have a lower tolerance to hypoglycemia. When using insulin, a relatively loose glucose-lowering treatment strategy and target value should be adopted to avoid the occurrence of hypoglycemia."
    },
    {
      "paragraph_id": "22",
      "paragraph": "4.肾功能不全时肾脏对胰岛素的降解明显减少，同时胰岛素排出速率下降，胰岛素可能在体内蓄积，患者出现氮质血症即血液中的尿素氮达9mmol[/L(25mg/d1)以上、肌酐达178μmol/L以上时，应根据血糖的监测及时减少和调整胰岛素的用量，使血糖维持在适当的范围内。胰岛素应优先选择短效、速效剂型。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.肾功能不全时肾脏对胰岛素的降解明显减少，同时胰岛素排出速率下降，胰岛素可能在体内蓄积，患者出现氮质血症即血液中的尿素氮达9mmol[/L(25mg/d1)以上、肌酐达178μmol/L以上时，应根据血糖的监测及时减少和调整胰岛素的用量，使血糖维持在适当的范围内。",
          "start_idx": 0,
          "end_idx": 133,
          "entities": [
            {
              "entity_id": "T226",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T227",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T228",
              "entity": "肾脏对胰岛素的降解明显减少",
              "entity_type": "Pathogenesis",
              "start_idx": 8,
              "end_idx": 21,
              "entity_en": "Renal degradation of insulin is significantly reduced"
            },
            {
              "entity_id": "T229",
              "entity": "胰岛素排出速率下降",
              "entity_type": "Pathogenesis",
              "start_idx": 24,
              "end_idx": 33,
              "entity_en": "Decreased insulin secretion rate"
            },
            {
              "entity_id": "T230",
              "entity": "胰岛素可能在体内蓄积",
              "entity_type": "Pathogenesis",
              "start_idx": 34,
              "end_idx": 44,
              "entity_en": "Insulin may accumulate in the body"
            },
            {
              "entity_id": "T231",
              "entity": "氮质血症",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 53,
              "entity_en": "Azotemia"
            },
            {
              "entity_id": "T232",
              "entity": "尿素氮",
              "entity_type": "Test_items",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "Urea nitrogen"
            },
            {
              "entity_id": "T233",
              "entity": "肌酐",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 84,
              "entity_en": "Creatinine"
            },
            {
              "entity_id": "T234",
              "entity": "达178μmol/L以上",
              "entity_type": "Test_Value",
              "start_idx": 84,
              "end_idx": 96,
              "entity_en": "Reach 178μmol/L or above"
            },
            {
              "entity_id": "T235",
              "entity": "达9mmol[/L(25mg/d1)以上",
              "entity_type": "Test_Value",
              "start_idx": 61,
              "end_idx": 81,
              "entity_en": "Reach 9mmol/L (25mg/d1) or more"
            },
            {
              "entity_id": "T236",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 116,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T237",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 121,
              "end_idx": 123,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T239",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 101,
              "end_idx": 103,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R85",
              "head_entity_id": "T227",
              "tail_entity_id": "T226"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R86",
              "head_entity_id": "T228",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R87",
              "head_entity_id": "T229",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R88",
              "head_entity_id": "T230",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R89",
              "head_entity_id": "T232",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R90",
              "head_entity_id": "T233",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R91",
              "head_entity_id": "T239",
              "tail_entity_id": "T231"
            }
          ],
          "sentence_en": "4. When renal function is impaired, the degradation of insulin by the kidney is significantly reduced, and the insulin excretion rate decreases. Insulin may accumulate in the body. When patients develop azotemia, that is, blood urea nitrogen reaches 9mmol[/L (25mg/d1) or more, and creatinine reaches 178μmol/L or more, the dosage of insulin should be reduced and adjusted in time according to blood sugar monitoring to maintain blood sugar within an appropriate range."
        },
        {
          "sentence_id": "1",
          "sentence": "胰岛素应优先选择短效、速效剂型。",
          "start_idx": 133,
          "end_idx": 149,
          "entities": [
            {
              "entity_id": "T238",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "Insulin should preferably be in the form of short-acting and rapid-acting formulations."
        }
      ],
      "paragraph_en": "4. In case of renal insufficiency, the degradation of insulin by the kidney is significantly reduced, and the insulin excretion rate decreases at the same time. Insulin may accumulate in the body. When patients develop azotemia, that is, blood urea nitrogen reaches 9mmol/L (25mg/d1) or more, and creatinine reaches 178μmol/L or more, the dosage of insulin should be reduced and adjusted in time according to blood sugar monitoring to maintain blood sugar within an appropriate range. Short-acting and rapid-acting insulin should be preferred."
    },
    {
      "paragraph_id": "23",
      "paragraph": "5.在治疗过程中，应加强患者教育，通过多学科的专业合作，提升患者的自我管理能力。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.在治疗过程中，应加强患者教育，通过多学科的专业合作，提升患者的自我管理能力。",
          "start_idx": 0,
          "end_idx": 40,
          "entities": [],
          "relations": [],
          "sentence_en": "5. During the treatment process, patient education should be strengthened and the patient's self-management ability should be improved through multidisciplinary professional cooperation."
        }
      ],
      "paragraph_en": "5. During the treatment process, patient education should be strengthened and the patient's self-management ability should be improved through multidisciplinary professional cooperation."
    },
    {
      "paragraph_id": "24",
      "paragraph": "6.对于注射胰岛素的患者，必须进行自我血糖监测。监测的频率取决于治疗的目标和方式[具体可参考：中国血糖监测临床应用指南(2011年版)]。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "6.对于注射胰岛素的患者，必须进行自我血糖监测。监测的频率取决于治疗的目标和方式[具体可参考：中国血糖监测临床应用指南(2011年版)]。",
          "start_idx": 0,
          "end_idx": 69,
          "entities": [
            {
              "entity_id": "T240",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T241",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "injection"
            },
            {
              "entity_id": "T242",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T243",
              "entity": "自我血糖监测",
              "entity_type": "Test_items",
              "start_idx": 17,
              "end_idx": 23,
              "entity_en": "Self-monitoring of blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R92",
              "head_entity_id": "T241",
              "tail_entity_id": "T240"
            }
          ],
          "sentence_en": "6. For patients who inject insulin, self-blood glucose monitoring is required. The frequency of monitoring depends on the goal and method of treatment [For details, please refer to: China Blood Glucose Monitoring Clinical Application Guidelines (2011 Edition)]."
        }
      ],
      "paragraph_en": "6. For patients who inject insulin, self-blood glucose monitoring is necessary. The frequency of monitoring depends on the goal and method of treatment [For details, please refer to: China Blood Glucose Monitoring Clinical Application Guide (2011 Edition)]."
    },
    {
      "paragraph_id": "25",
      "paragraph": "基于以上，成人2型糖尿病胰岛素临床应用中国专家共识推荐如下：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "基于以上，成人2型糖尿病胰岛素临床应用中国专家共识推荐如下：",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T244",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T245",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 7,
              "end_idx": 9,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T246",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R93",
              "head_entity_id": "T245",
              "tail_entity_id": "T244"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R94",
              "head_entity_id": "T246",
              "tail_entity_id": "T244"
            }
          ],
          "sentence_en": "Based on the above, the Chinese expert consensus on the clinical application of insulin in adults with type 2 diabetes recommends the following:"
        }
      ],
      "paragraph_en": "Based on the above, the Chinese expert consensus on the clinical application of insulin in adults with type 2 diabetes recommends the following:"
    },
    {
      "paragraph_id": "26",
      "paragraph": "合理把握胰岛素启动治疗时机。新诊断2型糖尿病患者HbA1c≥9.0%同时合并明显临床症状，或合并严重并发症，2种或2种以上口服降糖药次大剂量治疗3个月后仍不达标者(HbA1c≥7.0%)，应启动胰岛素治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "合理把握胰岛素启动治疗时机。新诊断2型糖尿病患者HbA1c≥9.0%同时合并明显临床症状，或合并严重并发症，2种或2种以上口服降糖药次大剂量治疗3个月后仍不达标者(HbA1c≥7.0%)，应启动胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 103,
          "entities": [
            {
              "entity_id": "T247",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T248",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 22,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T249",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T250",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T251",
              "entity": "≥9.0%",
              "entity_type": "Test_Value",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "≥9.0%"
            },
            {
              "entity_id": "T252",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 61,
              "end_idx": 63,
              "entity_en": "oral"
            },
            {
              "entity_id": "T253",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 87,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T254",
              "entity": "≥7.0%",
              "entity_type": "Test_Value",
              "start_idx": 87,
              "end_idx": 92,
              "entity_en": "≥7.0%"
            },
            {
              "entity_id": "T255",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 100,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R95",
              "head_entity_id": "T249",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R96",
              "head_entity_id": "T250",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R97",
              "head_entity_id": "T253",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R98",
              "head_entity_id": "T255",
              "tail_entity_id": "T248"
            }
          ],
          "sentence_en": "Reasonable timing for initiating insulin treatment: Newly diagnosed type 2 diabetes patients with HbA1c ≥ 9.0% and obvious clinical symptoms or severe complications, who still fail to reach the target (HbA1c ≥ 7.0%) after 3 months of high-dose treatment with 2 or more oral hypoglycemic drugs, should start insulin treatment."
        }
      ],
      "paragraph_en": "Reasonable timing for initiating insulin treatment: Newly diagnosed type 2 diabetes patients with HbA1c ≥ 9.0% and obvious clinical symptoms or severe complications, who still fail to reach the target (HbA1c ≥ 7.0%) after 3 months of high-dose treatment with 2 or more oral hypoglycemic drugs, should start insulin treatment."
    },
    {
      "paragraph_id": "27",
      "paragraph": "基础胰岛素或预混胰岛素均可作为胰岛素起始治疗方案。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "基础胰岛素或预混胰岛素均可作为胰岛素起始治疗方案。",
          "start_idx": 0,
          "end_idx": 25,
          "entities": [
            {
              "entity_id": "T256",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T257",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 11,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T258",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "Either basal insulin or premixed insulin can be used as the initial insulin therapy."
        }
      ],
      "paragraph_en": "Either basal insulin or premixed insulin can be used as the initial insulin therapy."
    },
    {
      "paragraph_id": "28",
      "paragraph": "应综合考虑患者病情、经济能力等各方面的因素，对血糖控制的风险与益处、成本与效益以及可行性进行科学评估，选择合理的胰岛素。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "应综合考虑患者病情、经济能力等各方面的因素，对血糖控制的风险与益处、成本与效益以及可行性进行科学评估，选择合理的胰岛素。",
          "start_idx": 0,
          "end_idx": 60,
          "entities": [
            {
              "entity_id": "T259",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T260",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 56,
              "end_idx": 59,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "Comprehensive consideration should be given to factors such as the patient's condition and financial ability, and a scientific assessment should be made of the risks and benefits, costs and benefits, and feasibility of blood sugar control to select reasonable insulin."
        }
      ],
      "paragraph_en": "Comprehensive consideration should be given to factors such as the patient's condition and financial ability, and a scientific assessment should be made of the risks and benefits, costs and benefits, and feasibility of blood sugar control to select reasonable insulin."
    }
  ]
}